Abstract | PURPOSE: Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response (CR) or partial response (PR) with ≤ three abnormal skeletal areas on iodine 123-metaiodobenzylguanidine ([123I] mIBG) scintigraphy and no bone marrow disease proceed to high dose therapy (HDT). In this study, topotecan- vincristine- doxorubicin (TVD) was evaluated in patients failing to achieve these criteria, with the aim of improving the metastatic response rate. MATERIALS AND METHODS: Patients with metastatic high-risk neuroblastoma who had not achieved the SIOPEN criteria for HDT after induction received two courses of topotecan 1.5 mg/m2/day for 5 days, followed by a 48-hour infusion of vincristine, 2 mg/m2, and doxorubicin, 45 mg/m2. RESULTS: Sixty-three patients were eligible and evaluable. Following two courses of TVD, four (6.4%) patients had an overall CR, while 28 (44.4%) had a PR with a combined response rate of 50.8% (95% confidence interval [CI], 37.9 to 63.6). Of these, 23 patients achieved a metastatic CR or a PR with ≤ 3 mIBG skeletal areas and no bone marrow disease (36.5%; 95% CI, 24.7 to 49.6) and were eligible to receive HDT. Toxicity was mostly haematological, affecting 106 of the 126 courses (84.1%; 95% CI, 76.5 to 90.0), and dose reduction was necessary in six patients. Stomatitis was the second most common nonhematological toxicity, occurring in 20 patients (31.7%). CONCLUSION: TVD was effective in improving the response rate of high-risk neuroblastoma patients after induction with COJEC enabling them to proceed to HDT. However, the long-term benefits of TVD needs to be determined in randomized clinical trials.
|
Authors | Loredana Amoroso, Giovanni Erminio, Guy Makin, Andrew D J Pearson, Penelope Brock, Dominique Valteau-Couanet, Victoria Castel, Marlène Pasquet, Genevieve Laureys, Caroline Thomas, Roberto Luksch, Ruth Ladenstein, Riccardo Haupt, Alberto Garaventa, SIOPEN Group |
Journal | Cancer research and treatment
(Cancer Res Treat)
Vol. 50
Issue 1
Pg. 148-155
(Jan 2018)
ISSN: 2005-9256 [Electronic] Korea (South) |
PMID | 28324923
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Topoisomerase I Inhibitors
- Vincristine
- Topotecan
- Doxorubicin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Neuroblastoma
(drug therapy, pathology)
- Risk Factors
- Topoisomerase I Inhibitors
(administration & dosage)
- Topotecan
(administration & dosage)
- Vincristine
(administration & dosage)
|